Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study

QR Code

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study

Abstract Background According to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) showed improved overall survival compared to fluorouracil alone for patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy....

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Se Jun Park, Hyunho Kim, Kabsoo Shin, Tae Ho Hong, Ja Hee Suh, Myung Ah Lee
Format:	article
Langue:	EN
Publié:	BMC 2021
Sujets:	Pancreatic cancer Liposomal irinotecan Gemcitabine-refractory Second-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/4925642ab4544182841d608bafad7bf1
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
par: Ko AH
Publié: (2016)

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
par: Hélène Bellio, et autres
Publié: (2021)

pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment
par: Shirleide Santos Nunes, et autres
Publié: (2021)

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
par: Jiaojiao Suo, et autres
Publié: (2021)

Externally Triggered Novel Rapid-Release Sonosensitive Folate-Modified Liposomes for Gemcitabine: Development and Characteristics
par: Omar MM, et autres
Publié: (2021)

Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells
par: Han NK, et autres
Publié: (2016)

Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck
par: Ammar Sukari, et autres
Publié: (2015)

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)
par: Florian Gebauer, et autres
Publié: (2021)

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
par: Jinsheng Ding, et autres
Publié: (2021)

Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis
par: Shuo Yu, et autres
Publié: (2021)

Survival and relative dose intensity of 5-fluorouracil, oxaliplatin and irinotecan in real-life treatment of metastatic colorectal cancer
par: Ilfad Blazevic, et autres
Publié: (2020)

Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer
par: Chen YQ, et autres
Publié: (2021)

ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma
par: Farnaz Sedigheh Takhsha, et autres
Publié: (2021)

Gemcitabina en 4 pacientes con colangiocarcinoma: Report of four cases
par: Gallardo E,Jorge, et autres
Publié: (2001)

Hydrophobically modified chitosan nanoliposomes for intestinal drug delivery
par: Zariwala MG, et autres
Publié: (2018)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
par: Christian Möhring, et autres
Publié: (2021)

Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy
par: Sunwang Xu, et autres
Publié: (2021)

Optimization of nanoemulsion containing gemcitabine and evaluation of its cytotoxicity towards human fetal lung fibroblast (MRC5) and human lung carcinoma (A549) cells
par: Wahgiman NA, et autres
Publié: (2019)

TPH1 and 5-HT<sub>7</sub> Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma
par: Prakash Chaudhary, et autres
Publié: (2021)

Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
par: Tai-Jan Chiu, et autres
Publié: (2021)

An Engineered Specificity of Anti-Neoplastic Agent Loaded Magnetic Nanoparticles for the Treatment of Breast Cancer
par: Anroop B. Nair, et autres
Publié: (2021)

Thrombotic Microangiopathy Associated with Gemcitabine in Non-Small Cell Lung Cancer: A Case Report
par: Tadahiro Kuribayashi, et autres
Publié: (2021)

Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
par: Cao,Xuebing, et autres
Publié: (2016)

CD95L Inhibition Impacts Gemcitabine-Mediated Effects and Non-Apoptotic Signaling of TNF-α and TRAIL in Pancreatic Tumor Cells
par: Khalid Rashid, et autres
Publié: (2021)

Self-Monitoring and Self-Delivery of Self-Assembled Fluorescent Nanoparticles in Cancer Therapy
par: Liu H, et autres
Publié: (2021)

Regorafenib in metastatic colorectal cancer: more data for clinical decisions
par: Vladislav V. Petkau, et autres
Publié: (2021)

Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study
par: Coriat R, et autres
Publié: (2016)

A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
par: Chadi Nabhan, et autres
Publié: (2011)

Eficacia de gemcitabina en cáncer de vesícula biliar.: Experiencia inicial en cuatro casos
par: Gallardo E,Jorge, et autres
Publié: (2000)

Exosomal lncRNA UCA1 Derived From Pancreatic Stellate Cells Promotes Gemcitabine Resistance in Pancreatic Cancer via the SOCS3/EZH2 Axis
par: Yuan Chi, et autres
Publié: (2021)

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer
par: Liu L, et autres
Publié: (2017)

Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer
par: Bai F, et autres
Publié: (2018)

The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3
par: Yoichi Takakusagi, et autres
Publié: (2022)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
par: Guo ZY, et autres
Publié: (2018)

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
par: Karen Aughton, et autres
Publié: (2021)

Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas
par: David Machover, et autres
Publié: (2021)

Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy
par: Laure Doisy, et autres
Publié: (2021)

Transferrin and folic acid co-modified bufalin-loaded nanoliposomes: preparation, characterization, and application in anti-cancer activity
par: Chen Q, et autres
Publié: (2018)

Folate receptor targeting of radiolabeled liposomes reduces intratumoral liposome accumulation in human KB carcinoma xenografts
par: Christensen E, et autres
Publié: (2018)

Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
par: Singh S
Publié: (2018)